Ernexa Therapeutics Inc. (ERNA) Gross Margin (2010 - 2024)
Ernexa Therapeutics' (ERNA) quarterly Gross Margin came in at 5.26% in Q4 2024, up 10526.0% YoY from N/an in Q1 2024, and down 95.31% on a QoQ basis from 112.32% in Q3 2024.
Ernexa Therapeutics Inc. (ERNA) Gross Margin (2010 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNA) has 13 years of Gross Margin data on file, last reported at 5.26% in Q4 2024.
- Quarterly Gross Margin rose 10526.0% year-over-year to 5.26% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 81.0% (up 24900.0% YoY) and the FY2024 annual result came in at 81.0%, up 24900.0% from the prior year.
- Gross Margin declined to 5.26% in Q4 2024, from 112.32% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 112.32% in Q3 2024 to a low of 135.29% in Q3 2023.
- A 3-year average of 10.63% and a median of 5.26% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2020 — Gross Margin plunged 2489 bps — and 2024, when it surged 24761 bps.
- Tracing ERNA's Gross Margin over 3 years: stood at 47.83% in 2020, then slumped by 309 bps to 100.0% in 2023, then jumped by 105 bps to 5.26% in 2024.
- The last three Gross Margin figures came in at 5.26% (Q4 2024), 112.32% (Q3 2024), and 102.13% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.26% |
| Sep 30, 2024 | 112.32% |
| Jun 30, 2024 | -102.13% |
| Mar 31, 2024 | -29.79% |
| Dec 31, 2023 | -100.00% |
| Sep 30, 2023 | -135.29% |
| Dec 31, 2020 | 47.83% |
| Sep 30, 2020 | 45.77% |
| Mar 31, 2020 | 60.32% |
| Dec 31, 2019 | 43.15% |
| Sep 30, 2019 | 70.66% |
| Jun 30, 2019 | 67.15% |
| Mar 31, 2019 | 69.29% |
| Dec 31, 2018 | 65.35% |
| Sep 30, 2018 | 64.77% |
| Jun 30, 2018 | 65.72% |
| Mar 31, 2018 | 65.86% |
| Dec 31, 2017 | 67.11% |
| Sep 30, 2017 | 70.39% |
| Jun 30, 2017 | 70.61% |